

BILIARY ATRESIA

Association between cholecystectomy for gallstone disease and risk factors for cardiovascular disease 11: 85-oa

Unusual cause of common bile duct dilatation in asymptomatic elderly patient: right hepatic artery syndrome 11: 150-le

Intestinal nuclear bile acid receptor FXR and cholestasis 11: 152-lne

Recurrent pyogenic cholangitis in a case with congenital biliary anomaly 11: 268-cr

Outcomes of choledochal cysts with or without intrahepatic involvement in children after extrahepatic cyst excision and Roux-en-Y hepaticojejunostomy 11: 536-oa

Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanicular phospholipid and bile salt transporters 11: 710-cr

Bile acids content in brain of common duct ligated rats 11: 930-oa

BLEEDING VARICES

Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding 11: 369-oa

Can ARFI elastography predict the presence of significant esophageal varices in newly diagnosed cirrhotic patients? 11: 519-oa

Splenectomy in cirrhosis with hypersplenism: improvement in cytopenias, child's status and institution of specific treatment for hepatitis C with success 11: 921-oa

CIRRHOSIS

Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality 11: 90-oa

Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis 11: 100-oa

Acute kidney injury in critically ill cirrhotic patients: a review 11: 301-cre

Hospital performance reports based on severity adjusted mortality rates in patients with cirrhosis depend on the method of risk adjustment 11: 526-oa

Decreased serum total T3 level in hepatitis B and C related cirrhosis by severity of liver damage 11: 667-oa

DIABETES

Glycogenic hepatopathy associated with type 1 diabetes mellitus as a cause of recurrent liver damage 11: 554-cr

SUBJECT INDEX VOLUME 11, 2012

Elevated alanine aminotransferase levels are associated with impaired fasting glucose and type 2 diabetes in obese women 11: 966-le

HEPATIC

Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy 11: 96-oa

Primary hepatic amyloidosis: a mini literature review and five cases report 11: 721-cr
Room-temperature susceptometry predicts biopsy-determined hepatic iron in patients with elevated serum ferritin 11: 77-oa

HEPATITIS

Intrafamilial seropositivity of hepatitis in patients with hepatitis B and C virus in hepatitis clinic in Hamadan, Iran 11:32-oa

Prevalence of hepatitis A, B and C serological markers in children from western Mexico 11: 194-oa

Fulminant hepatitis during self-medication with conjugated linoleic acid 11: 265-cr

Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection? 11:320-oa

Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt 11: 464-oa

Acute autoimmune hepatitis presenting with peripheral blood eosinophilia 11: 559-cr

Pegylated interferon, but not conventional interferon therapy induced severe skin lesions 11: 570-le

Occult HBV infection among anti-HBc positive HIV-infected patients in apex referral centre, Eastern India 11: 870-oa

A

Hepatitis A vaccination in healthcare personnel 11: 326-oa

Clinical course and management of acute hepatitis A infection in adults 11: 652-oa

B

Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico 11: 47-oa

Hepatitis B viral load and risk of HBV-related liver disease: from East to West? 11: 164-cre

Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B 11: 202-oa

Different models in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure 11: 311-oa

Hepatitis B virus prevalence and vaccination response in health care workers and students at the Federal University of Bahia, Brazil 11: 330-oa

Genotype/Subgenotype distribution of hepatitis B virus among hemodialysis patients with chronic hepatitis B 11: 849-oa

Epidemiological, clinical and laboratory features of chronic hepatitis B infection in a cohort of immigrant and Italian patients from Ferrara, Italy 11: 862-oa

C

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients 11: 15-oa

Serum lipids and chronic hepatitis C genotype 4: interaction and significance 11: 37-oa

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial 11: 52-oa

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT 11: 186-oa

Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study 11: 338-oa

Successful antiviral treatment of chronic hepatitis C in patients with rare comorbidities. Two case-reports 11: 404-cr

Does the persistently normal aminotransferase levels in hepatitis C still have relevance? 11: 412-le

Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients 11: 450-oa

The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico 11: 550-ed

Atherosclerosis and chronic hepatitis C 11: 574-lne

The epidemiologic burden of hepatitis C virus infection in Latin America 11: 623-crc

Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? 11: 648-oa

Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects 11: 658-oa

Silybin/Silymarin treatment in chronic hepatitis C 11: 731-lne

Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment 11: 827-crc

IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population 11: 876-oa

Dorsal root ganglionopathy in a hepatitis C patient: a case report 11: 958-cr

Increased mortality in chronic HCV infection 11: 967-lne

Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis c 11: 855-oa

E

Review of the neurological manifestations of hepatitis E infection 11: 618-crc

HEPATOGENESIS

Does the size of the needle influence the number of portal tracts obtained through percutaneous liver biopsy? 11: 691-oa

Inflammatory myofibroblastic tumor of the liver 11: 708-ih

HEPATOCELLULAR CARCINOMA

Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes 11: 118-oa

Cellular microRNA and the tumorigenesis of hepatocellular carcinoma 11: 272-lne

Prevention of hepatocellular carcinoma: a concise review of contemporary issues 11: 284-crc

Cardiac metastasis of hepatocellular carcinoma in a young non-cirrhotic patient, to the left ventricle 11: 392-ih

Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma 11: 487-oa

Transforming growth factor a immunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic liver tissue 11: 495-oa

Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma 11: 899-oa

Thyroid-like cholangiocarcinoma of the liver: an unusual morphologic variant with follicular, trabecular and insular patterns 11: 961-cr

HEPATOTOXICITY

Hepatotoxicity associated with statins 11: 418-lne

Initially purported hepatotoxicity by *Pelargonium sidoides*: the dilemma of pharmacovigilance and proposals for improvement 11: 500-oa

Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes 11: 564-cr

Greater Celandine hepatotoxicity:
a clinical review 11: 838-cre

Protective role of standardized *Feronia*
limonia stem bark methanolic extract against
carbon tetrachloride induced hepatotoxicity 11: 935-oa

NAT2 genetic polymorphisms and
anti-tuberculosis drug-induced hepatotoxicity
in Chinese community population 11: 700-oa

HYPERTENSION

Massive avascular malformations causing life
threatening portal hypertension 11: 552-ih

Idiopathic portal hypertension with multiple
hepatic hyperplastic nodules supplied by portal vein 11: 572-le

LIVER

Shark liver oil: hidden dangers 11: 728-le

Abnormal liver function tests in a patient
with myotonic dystrophy type 1 11: 130-cr

Acute liver failure due to non-exertional
heatstroke after sauna 11: 138-cr

Evidence for liver injury in the
setting of obstructive sleep apnea 11: 228-oa

Increased mortality from acute liver failure in Mexico 11: 257-oa

Portal vein aneurysm: is it an incidental finding only? 11: 263-ih

Treatment of hyperferritinemia 11: 294-cre

Association between butyrylcholinesterase
activity and low-grade systemic inflammation 11: 356-oa

Hepatoprotective effect of the selective
mineralocorticoid receptor antagonist,
eplerenone against carbon
tetrachloride-induced liver injury in rats 11: 384-oa

Noninvasive markers of fibrosis:
key concepts for improving accuracy in
daily clinical practice 11: 426-cre

Building a Spanish-Latin American
network on drug induced liver injury:
much to get from a joint collaborative initiative 11: 544-ed

Role of nitric oxide in liver regeneration 11: 636-cre

An unusual cause of portal cavernomatosis 11: 949-ih

Spontaneous bacterial peritonitis caused
by *Listeria monocytogenes*:
a case report and literature review 11: 955-cr

LIVER DISEASE

Smoking as a risk factor for autoimmune liver disease:
what we can learn from primary biliary cirrhosis 11: 7-cre

Serum homocysteine levels in patients
with nonalcoholic fatty liver disease 11: 68-oa

Amoebic liver abscess production by *Entamoeba dispar* .. 11: 107-oa

High coffee intake is associated with
lower grade nonalcoholic fatty liver disease:
the role of peripheral antioxidant activity 11: 350-oa

Living *Fasciola hepatica* in biliary tree: a case report 11: 395-cr

Hepatic hemodynamics and transient
elastography in alcoholic foamy degeneration:
report of 2 cases 11: 399-cr

Acetylcholinesterase and butyrylcholinesterase
as markers of low-grade systemic inflammation 11: 409-le

Risk factors for in-hospital mortality of
patients with high model for end-stage liver disease
scores following living donor liver transplantation 11: 471-oa

Polycystic liver disease: a clinical review 11: 819-cre

Alcohol effects on liver diseases: good or bad buddy? 11: 944-ed

NONALCOHOLIC FATTY LIVER DISEASE

Is it appropriate to study blood ghrelin and
obestatin in non-alcoholic fatty liver disease (NAFLD)
without using protease inhibitors? 11: 145-le

Hormone replacement therapy in
menopausal women: risk factor or protection
to nonalcoholic fatty liver disease? 11: 147-le

Transient elastography in non-alcoholic
fatty liver disease 11: 172-cre

Gut microbiota and nonalcoholic fatty liver disease 11: 440-cre

Correlation of adipose tissue with liver
histology in Asian Indian patients with
nonalcoholic fatty liver disease (NAFLD) 11: 478-oa

PERITONITIS

Rapid diagnosis of spontaneous bacterial
peritonitis using leukocyte esterase reagent
strips in Emergency Department:
Uri-Quick Clini-10SG® vs. Multistix 10SG® 11: 696-oa

Prognostic factors associated with in-hospital
mortality in patients with spontaneous
bacterial peritonitis 11: 915-oa

Glisson's capsule blistering after
hyperthermic intraperitoneal chemotherapy 11: 128-ih

SYNDROME

Budd-Chiari syndrome after treatment
with budesonide in a cirrhotic patient with
autoimmune hepatitis 11: 143-le

Renal and circulatory effects of
large volume plasma expansion in patients
with hepatorenal syndrome type 1 11: 232-oa

Serum adipocyte fatty acid binding
protein in liver transplant recipients and
the metabolic syndrome 11: 343-oa

STUDIES

- Region 11 MELD Na exception prospective study 11: 62-*oa*
- Prognostic markers in cirrhotic patients requiring intensive care: a comparative prospective study 11: 513-*oa*
- Response to different therapeutic approaches in Wilson disease. A long-term follow up study 11: 907-*oa*
- Epidemiologic trends in HBV infections at a reference centre in Turkey: an 11-year retrospective analysis 11: 672-*oa*
- The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study 11: 240-*oa*
- A comparison study of local injection and radiofrequency ablation therapy for traumatic portal vein injury guided by contrast-enhanced ultrasonography 11: 249-*oa*
- Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study 11: 364-*oa*

THROMBOSIS

- A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients 11: 686-*oa*

TRANSPLANTATION

- A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients 11: 179-*cre*
- Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report 11: 951-*cr*
- Primary hepatic neuroendocrine tumour requiring live donor liver transplantation: case report and concise review 11: 715-*cr*
- Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease 11: 213-*oa*
- Liver transplantation for autoimmune hepatitis in Peru: outcomes and recurrence 11: 222-*oa*
- Causes of death after liver transplantation 11: 415-*le*
- Liver transplantation in the critically ill: donation after cardiac death compared to donation after brain death grafts 11: 679-*oa*
- Health-related quality of life in Egyptian patients after liver transplantation 11: 882-*oa*
- Steatotic livers. Can we use them in OLTx? Outcome data from a prospective baseline liver biopsy study 11: 891-*oa*
- An unusual cause of cancer mimicry following liver transplantation 11: 134-*cr*